LU91362I2 - Palipéridone et ses dérivés pharmaceutiquement acceptables (INVEGA) - Google Patents

Palipéridone et ses dérivés pharmaceutiquement acceptables (INVEGA)

Info

Publication number: LU91362I2
Authority: LU; Luxembourg
Prior art keywords: pharmaceutically acceptable; invega; paliperidone; compounds; acceptable derivatives
Prior art date: 1988-11-07

Application number

LU91362C

Other languages

English (en)

Original Assignee

Janssen Pharmaceutica Nv

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1988-11-07

Filing date

2007-09-12

Publication date

2007-11-12

2007-09-12 Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv

2007-11-12 Publication of LU91362I2 publication Critical patent/LU91362I2/fr

Links

PMXMIIMHBWHSKN-UHFFFAOYSA-N 3-{2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl}-9-hydroxy-2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCC(O)C4=NC=3C)=NOC2=C1 PMXMIIMHBWHSKN-UHFFFAOYSA-N 0.000 title 2
229940013946 invega Drugs 0.000 title 1
229960001057 paliperidone Drugs 0.000 title 1
150000001875 compounds Chemical class 0.000 abstract 3
125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 2
239000008194 pharmaceutical composition Substances 0.000 abstract 2
FFESGTAUFAZQRI-UHFFFAOYSA-N 3-piperidin-1-yl-1,2-benzoxazole Chemical class C1CCCCN1C1=NOC2=CC=CC=C12 FFESGTAUFAZQRI-UHFFFAOYSA-N 0.000 abstract 1
239000002253 acid Substances 0.000 abstract 1
239000004480 active ingredient Substances 0.000 abstract 1
239000000164 antipsychotic agent Substances 0.000 abstract 1
125000001475 halogen functional group Chemical group 0.000 abstract 1
229910052739 hydrogen Inorganic materials 0.000 abstract 1
239000001257 hydrogen Substances 0.000 abstract 1
125000004435 hydrogen atom Chemical class [H]* 0.000 abstract 1
125000004356 hydroxy functional group Chemical group O* 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Veterinary Medicine (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Psychiatry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

LU91362C 1988-11-07 2007-09-12 Palipéridone et ses dérivés pharmaceutiquement acceptables (INVEGA) LU91362I2 (fr)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US26785788A	1988-11-07	1988-11-07

Publications (1)

Publication Number	Publication Date
LU91362I2 true LU91362I2 (fr)	2007-11-12

Family

ID=23020416

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
LU91362C LU91362I2 (fr)	1988-11-07	2007-09-12	Palipéridone et ses dérivés pharmaceutiquement acceptables (INVEGA)

Country Status (21)

Country	Link
EP (1)	EP0368388B1 (fr)
JP (1)	JP2758045B2 (fr)
KR (1)	KR0146053B1 (fr)
AT (1)	ATE122349T1 (fr)
AU (1)	AU614437B2 (fr)
CA (1)	CA2000786C (fr)
CL (1)	CL43432B (fr)
CY (2)	CY1926A (fr)
DE (2)	DE122007000081I2 (fr)
DK (1)	DK169923B1 (fr)
ES (1)	ES2075036T3 (fr)
FI (1)	FI92201C (fr)
HK (1)	HK131696A (fr)
IE (1)	IE66370B1 (fr)
IL (1)	IL92208A0 (fr)
LU (1)	LU91362I2 (fr)
NL (1)	NL300298I2 (fr)
NO (2)	NO173015C (fr)
NZ (1)	NZ231062A (fr)
PT (1)	PT92206B (fr)
ZA (1)	ZA898436B (fr)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9008850D0 (en) *	1990-04-19	1990-06-13	Janssen Pharmaceutica Nv	Novel 2,9-disubstituted-4h-pyridol(1,2-a)pyrimidin-4-ones
US5378714A (en) *	1991-11-27	1995-01-03	Novo Nordisk A/S	Antipsychotic piperidine derivatives
JPH07502268A (ja) *	1991-11-27	1995-03-09	ノボ　ノルディスク　アクティーゼルスカブ	化学化合物、それらの製法および使用
ES2050069B1 (es) *	1992-07-10	1994-12-16	Vita Invest Sa	Procedimiento para la obtencion de 3-(2-(4-(6-fluoro-1,2-benzisoxazol-3-il)piperidino)etil)-2-metil-6,7,8,9-tetrahidro-4h-pirido(1,2-a) pirimidin-4-ona.
DK60593D0 (da) *	1993-05-26	1993-05-26	Novo Nordisk As	Kemiske forbindelser, deres fremstilling og anvendelse
DK60793D0 (da) *	1993-05-26	1993-05-26	Novo Nordisk As	Kemiske forbindelser, deres fremstilling og anvendelse
CN1074923C (zh) *	1993-11-19	2001-11-21	詹森药业有限公司	微囊密封的3-哌啶基取代的1,2-苯并异唑类和1,2-苯并异噻唑类
SI0730594T1 (en) *	1993-11-23	1999-12-31	Janssen Pharmaceutica N.V.	9-HYDROXY-PYRIDO (1,2-a)PYRIMIDIN-4-ONE ETHER DERIVATIVES
ES2085234B1 (es) *	1994-02-24	1997-01-16	Vita Invest Sa	Agente activo sobre el sistema nervioso central, procedimiento para su preparacion y composiciones farmaceuticas que lo contienen.
TW487572B (en) *	1996-05-20	2002-05-21	Janssen Pharmaceutica Nv	Aqueous suspensions of 9-hydroxyrisperidone fatty acid esters
US6028083A (en) *	1997-07-25	2000-02-22	Hoechst Marion Roussel, Inc.	Esters of (+)-α-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl) ethyl]-4-piperidinemethanol
UA72189C2 (uk) *	1997-11-17	2005-02-15	Янссен Фармацевтика Н.В.	Фармацевтична композиція, що містить водну суспензію субмікронних ефірів 9-гідроксирисперидон жирних кислот
ES2141671B1 (es) *	1997-12-26	2001-01-01	Vita Invest Sa	Compuesto pirimidinico activo sobre el sistema nervioso central, procedimiento para su preparacion y composiciones farmaceuticas que lo contienen.
WO1999059590A1 (fr) *	1998-05-18	1999-11-25	Sepracor Inc.	Compositions d'hydroxyrisperidone (+) et methodes associees
US6326362B1 (en)	1998-05-18	2001-12-04	Sepracor Inc.	(-)-phosphonorisperidone and (-)-sulforisperidone compositions and methods
US6342488B1 (en)	1998-08-18	2002-01-29	Sepracor, Inc.	Phosphonorisperidone and sulforisperidone compositions and methods
ES2197801B1 (es) *	2002-03-05	2005-03-16	Ferrer Internacional,S.A	Procedimiento de obtencion de la 3-(2-(4-(6-fluoro-benzo(d)isoxazol-3-il) piperidin-1-il)-etil)-2-metil-6,7,8,9-tetrahidro-4h-pirido-(1,2-a ) pirimidin-4-ona.
KR20040025224A (ko) *	2002-09-18	2004-03-24	주식회사 대웅	2-(2-메틸-4-옥소-6,7,8,9-테트라하이드로-4Ｈ-피리도[1,2-ａ]피리미딘-3-일)아세트알데히드 및 그 제조방법
EP1560814A1 (fr)	2002-11-13	2005-08-10	Synthon B.V.	Procede de fabrication de la risperidone et des intermediaires associes
ES2546268T3 (es)	2004-09-09	2015-09-22	Janssen Pharmaceutica Nv	Preparación de 9-hidroxi-3-(2-hidroxietil)-2-metil-4H-pirido[1,2-a]pirimidin-4-ona y sus cristales
US20070197591A1 (en)	2005-12-12	2007-08-23	Sandra Boom	Use of paliperidone for the treatment of a mental disorder in a psychiatric patient with reduced hepatic function
EP2133351A3 (fr) *	2006-08-14	2010-01-13	Teva Pharmaceutical Industries Ltd.	Forme cristalline de la 9-hydroxy-rispéridone (palipéridone)
ES2304336T1 (es)	2006-08-14	2008-10-16	Teva Pharmaceutical Industries Ltd.	Formas cristalinas de 9-hidroxi-risperidona (paliperidona).
EP2133352A3 (fr) *	2006-08-14	2010-01-13	Teva Pharmaceutical Industries Ltd.	Forme cristalline de la 9-hydroxy-rispéridone (palipéridone)
WO2008024415A2 (fr) *	2006-08-23	2008-02-28	Teva Pharmaceutical Insustries Ltd.	Procédé destiné à la synthèse de cmhtp et de ses intermédiaires
US7820816B2 (en)	2006-08-23	2010-10-26	Teva Pharmaceutical Industries Ltd.	Process for the synthesis of CMHTP and intermediates thereof
CN101600716A (zh)	2007-01-08	2009-12-09	阿特维斯集团公司	用于制备9-羟基-3-(2-氯乙基)-2-甲基-4H-吡啶并[1,2-a]嘧啶-4-酮盐酸盐的改进方法
BRPI0809837A2 (pt) *	2007-04-19	2014-11-11	Youxin Li	"composto para tratamento de distúrbios mentais, saldo do composto para tratamento de distúrbios mentais, composição farmacéutica e uso do composto para tratamento de distúrbios mentais"
WO2009010988A1 (fr) *	2007-07-19	2009-01-22	Natco Pharma Limited	Procédé amélioré, industriellement viable pour la préparation de palipéridone de haute pureté
EP2178872A1 (fr) *	2007-07-27	2010-04-28	Synthon B.V.	Dérivés de palipéridone
WO2009045489A2 (fr) *	2007-10-03	2009-04-09	Teva Pharmaceutical Industries Ltd.	Procédé de synthèse de cmhtp, un intermédiaire de la palipéridone
JP2010540676A (ja) *	2007-10-09	2010-12-24	シプラ・リミテッド	パリペリドン及びその医薬として許容し得る塩の製造方法、並びに該方法に使用する中間体
CL2008003667A1 (es) *	2007-12-10	2010-06-04	Synthon Bv	Proceso de preparacion de etil-6,7,8,9-tetrahidro-9-hidroxi-2-metil-4h-pirido[1,2-a]piridin-4-ona; y uno de los intermediarios considerados en el proceso descrito; util en la preparacion de paliperidona.
WO2009116071A2 (fr) *	2008-02-05	2009-09-24	Watson Pharma Private Limited	Procédé amélioré pour la préparation de palipéridone
EP2285804A4 (fr) *	2008-04-21	2011-09-14	Glenmark Generics Ltd	Procédé pour la fabrication d'intermédiaires de palipéridone
ES2625323T3 (es) *	2008-05-29	2017-07-19	Inke, S.A.	Proceso para preparar paliperidona e intermedios de la misma
EP2300467A4 (fr)	2008-06-16	2012-04-25	Msn Lab Ltd	Nouveaux procédés améliorés de préparation de la palipéridone
EP2321311B1 (fr) *	2008-07-11	2012-09-19	Synthon B.V.	Synthèse de palipéridone
US7932385B2 (en)	2008-07-11	2011-04-26	Synthon Bv	Paliperidone ketone
SI22856A (sl) *	2008-07-31	2010-02-26	Krka, Tovarna Zdravil, D.D., Novo Mesto	Proces za pripravo paliperidona
EP2161019A1 (fr)	2008-09-05	2010-03-10	KRKA, D.D., Novo Mesto	Composition pharmaceutique multi-particules à libération prolongée comportant de la palipéridone
EP2199293A1 (fr)	2008-12-22	2010-06-23	Chemo Ibérica, S.A.	Procédé à étape unique pour la préparation de palipéridone en son sel d'oxalate
EP2202234A1 (fr)	2008-12-24	2010-06-30	Laboratorios Lesvi, S.L.	Purification de la palipéridone
SI2275423T1 (sl)	2009-07-13	2012-06-29	Krka D.D., Novo Mesto	Postopek za sintezo paliperidona
WO2011018246A2 (fr)	2009-08-13	2011-02-17	Synthon B.V.	Composition de palipéridone à libération contrôlée
EP2343296A1 (fr)	2009-12-01	2011-07-13	Chemo Ibérica, S.A.	Procédé pour la purification de la palipéridone
WO2011074017A1 (fr) *	2009-12-17	2011-06-23	Alkem Laboratories Ltd.	Nouveau procédé de préparation de palipéridone
US8088594B2 (en) *	2010-03-16	2012-01-03	Saladax Biomedical Inc.	Risperidone immunoassay
WO2012035554A1 (fr) *	2010-09-14	2012-03-22	Megafine Pharma (P) Ltd.	Procédé amélioré de préparation de palipéridone très pure
JP5916746B2 (ja)	2010-11-15	2016-05-11	エージンバイオ，インコーポレイテッド	認知障害を処置するためのピリダジン誘導体、組成物、および方法
CN102153552B (zh) *	2011-03-01	2012-08-22	吉林大学	两种帕潘立酮药物共晶及其制备方法
CN102206210B (zh) *	2011-04-01	2014-07-02	常州市第四制药厂有限公司	一种6-氟-3-(4-哌啶基)-1，2-苯并异噁唑盐酸盐的生产方法
JP6440625B2 (ja)	2012-11-14	2018-12-19	ザ・ジョンズ・ホプキンス・ユニバーシティー	精神分裂病を処置するための方法および組成物
AU2014368961B2 (en)	2013-12-20	2019-10-17	Agenebio, Inc.	Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
EP3310785B1 (fr)	2015-06-19	2024-11-20	Agenebio, Inc.	Dérivés de benzodiazépine, compositions et méthodes de traitement de la déficience cognitive
US11505555B2 (en)	2016-12-19	2022-11-22	Agenebio, Inc.	Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
US20180170941A1 (en)	2016-12-19	2018-06-21	Agenebio, Inc.	Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
US11377445B2 (en)	2018-02-21	2022-07-05	Zenvision Pharma Llp	Derivatives of paliperidone and process for the preparation thereof
MX2020013927A (es)	2018-06-19	2021-03-02	Agenebio Inc	Derivados de benzodiazepina, composiciones y metodos para tratar el deterioro cognitivo.
WO2024039886A1 (fr)	2022-08-19	2024-02-22	Agenebio, Inc.	Dérivés de benzoazépine, compositions et méthodes de traitement de déficience cognitive
CN116003404B (zh) *	2022-12-14	2024-10-01	杭州同舟生物技术有限公司	一种利培酮人工半抗原、人工抗原及其制备方法和应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4342870A (en) *	1980-03-28	1982-08-03	Janssen Pharmaceutica N.V.	Novel 3-(1-piperidinylalkyl)-4H-pyrido[1,2-a]pyrimidin-4-one derivatives
US4804663A (en) *	1985-03-27	1989-02-14	Janssen Pharmaceutica N.V.	3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles

1989
- 1989-10-16 CA CA002000786A patent/CA2000786C/fr not_active Expired - Lifetime
- 1989-10-18 NZ NZ231062A patent/NZ231062A/xx unknown
- 1989-10-30 ES ES89202724T patent/ES2075036T3/es not_active Expired - Lifetime
- 1989-10-30 DE DE122007000081C patent/DE122007000081I2/de active Active
- 1989-10-30 EP EP89202724A patent/EP0368388B1/fr not_active Expired - Lifetime
- 1989-10-30 DE DE68922577T patent/DE68922577T2/de not_active Expired - Lifetime
- 1989-10-30 CY CY192689A patent/CY1926A/xx unknown
- 1989-10-30 AT AT89202724T patent/ATE122349T1/de active
- 1989-11-03 IL IL92208A patent/IL92208A0/xx not_active IP Right Cessation
- 1989-11-06 AU AU44436/89A patent/AU614437B2/en not_active Expired
- 1989-11-06 PT PT92206A patent/PT92206B/pt not_active IP Right Cessation
- 1989-11-06 IE IE356489A patent/IE66370B1/en not_active IP Right Cessation
- 1989-11-06 FI FI895261A patent/FI92201C/fi active Protection Beyond IP Right Term
- 1989-11-06 NO NO894411A patent/NO173015C/no not_active IP Right Cessation
- 1989-11-06 ZA ZA898436A patent/ZA898436B/xx unknown
- 1989-11-06 DK DK551989A patent/DK169923B1/da not_active IP Right Cessation
- 1989-11-07 KR KR1019890016114A patent/KR0146053B1/ko not_active Expired - Lifetime
- 1989-11-07 JP JP1289842A patent/JP2758045B2/ja not_active Expired - Lifetime
1996
- 1996-07-18 HK HK131696A patent/HK131696A/en not_active IP Right Cessation
2004
- 2004-05-20 CL CL200401183A patent/CL43432B/es active
2007
- 2007-09-12 LU LU91362C patent/LU91362I2/fr unknown
- 2007-10-15 CY CY200700025C patent/CY2007025I2/el unknown
- 2007-10-17 NL NL300298C patent/NL300298I2/nl unknown
- 2007-12-21 NO NO2007017C patent/NO2007017I2/no unknown

Also Published As

Publication number	Publication date
DK169923B1 (da)	1995-04-03
IE66370B1 (en)	1995-12-27
NO894411D0 (no)	1989-11-06
DK551989D0 (da)	1989-11-06
FI895261A0 (fi)	1989-11-06
ZA898436B (en)	1991-07-31
NO2007017I1 (no)	2008-01-14
FI92201C (fi)	1994-10-10
CA2000786A1 (fr)	1990-05-07
KR910009700A (ko)	1991-06-28
CY1926A (en)	1989-10-30
FI92201B (fi)	1994-06-30
NL300298I2 (nl)	2008-03-03
KR0146053B1 (ko)	1998-08-17
EP0368388B1 (fr)	1995-05-10
JPH02191276A (ja)	1990-07-27
HK131696A (en)	1996-07-26
DK551989A (da)	1990-05-08
NO894411L (no)	1990-05-08
AU614437B2 (en)	1991-08-29
IE893564L (en)	1990-05-07
NO173015C (no)	1993-10-13
NZ231062A (en)	1991-09-25
CL43432B (es)	2005-06-03
CY2007025I1 (el)	2009-11-04
DE122007000081I1 (de)	2008-02-28
ATE122349T1 (de)	1995-05-15
PT92206B (pt)	1995-07-06
AU4443689A (en)	1990-05-10
CA2000786C (fr)	1999-01-26
IL92208A0 (en)	1990-07-26
PT92206A (pt)	1990-05-31
NO173015B (no)	1993-07-05
JP2758045B2 (ja)	1998-05-25
DE122007000081I2 (de)	2010-01-28
EP0368388A2 (fr)	1990-05-16
ES2075036T3 (es)	1995-10-01
CY2007025I2 (el)	2009-11-04
NO2007017I2 (no)	2010-01-25
NL300298I1 (nl)	2007-12-03
DE68922577D1 (de)	1995-06-14
DE68922577T2 (de)	1995-09-28
EP0368388A3 (fr)	1991-07-17

Publication	Publication Date	Title
LU91362I2 (fr)	2007-11-12	Palipéridone et ses dérivés pharmaceutiquement acceptables (INVEGA)
EP0151824A3 (en)	1985-10-09	N-(4-piperidinyl) bicyclic condesed 2-imidazolamine derivatives
FI900085A0 (fi)	1990-01-08	Menetelmä terapeuttisesti käyttökelpoisten N-(pyrimidin- ja kondensoitu pyrimidin-4-oni)etyyli-piperidiini- ja piperatsiinijohdannaisten valmistamiseksi
NO176051C (no)	1995-01-25	Analogifremgangsmåte for fremstilling av terapeutisk aktive 3-piperazinylbenzazol-derivater
AU1810988A (en)	1988-12-22	Novel n-(4-piperidinyl)bicyclic condensed 2-imidazolamine derivatives
NO176608C (no)	1995-05-03	Analogifremgangsmåte for fremstilling av terapeutisk aktive 3-piperidinylindazol-derivater